Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferrous Salt vs. Liposomal Iron in Adult Women With Iron-Deficiency Anemia
NCT07556731Phase 3Not yet recruiting
- Sponsor
- Hospital General de México "Dr. Eduardo Liceaga"
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric pyrophosphate liposomal in iron deficiency anemia (IDA) (3 arms), sponsored by Hospital General de México "Dr. Eduardo Liceaga". Primary endpoint: Change in hemoglobin level at 3 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
ferric pyrophosphate liposomal
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT07556731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556731.